Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CCT251545 analog is a potent and selective CDK8/19 inhibitor (IC50: 5.1 nM and 5.6 nM, respectively). Mediator complex-associated kinases CDK8 and CDK19 are involved in the regulation of multiple transcription pathways. CDK8 plays as an oncogene in gastric and colorectal cancers through the activation of WNT signaling.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 329.00 | |
25 mg | Inquiry | $ 1,120.00 |
Description | CCT251545 analog is a potent and selective CDK8/19 inhibitor (IC50: 5.1 nM and 5.6 nM, respectively). Mediator complex-associated kinases CDK8 and CDK19 are involved in the regulation of multiple transcription pathways. CDK8 plays as an oncogene in gastric and colorectal cancers through the activation of WNT signaling. |
In vitro | In SW620 human colorectal carcinoma cells harbouring activating APC-mutation, Compound 51 inhibited phospho-STAT1SER727 ( IC50 :17.9 nM). It is a biomarker of CDK8 inhibition [1]. |
In vivo | In vivo mouse and rat PK experiments, The compound demonstrated medium in vivo clearance and Vd but low bioavailability in mice. In an SW620 colorectal carcinoma human tumor xenograft model, Compound 51 (5 mg/kg p.o. dose) inhibited phospho-STAT1SER727 in a time-dependent way. Compound 51 is an advanced chemical tool to further explore the efficacy, safety, and tolerability of dual CDK8/19 ligands [1]. |
Molecular Weight | 414.46 |
Formula | C23H22N6O2 |
CAS No. | T22633 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: > 20.7 mg/mL, Heating is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CCT251545 analogue, Compound 51 T22633 Others CCT-251545 analogue, Compound 51 inhibitor inhibit